KCM
SNDX icon

Kornitzer Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Kornitzer Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-28,800
Closed -$402K – 472
2017
Q2 		$402K Sell
28,800
-8,100
-22% -$92.6K 0.01% 443
2017
Q1 		$506K Hold
36,900
– – 0.01% 422
2016
Q4 		$265K Hold
36,900
– – 0.01% 451
2016
Q3 		$559K Sell
36,900
-8,600
-19% -$113K 0.01% 403
2016
Q2 		$448K Buy
45,500
+5,500
+14% +$75.4K 0.01% 408
2016
Q1 		$533K Buy
+40,000
New +$503K 0.01% 395

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Kornitzer Capital Management's SNDX Position: Q3 2017 in Review

Kornitzer Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q3 2017, closing a stake of 28,800 shares — an estimated $402K sold.

Kornitzer Capital Management first reported a position in SNDX in Q1 2016 and held it in 6 quarters. The position peaked at $559K in Q3 2016. 68 funds tracked by Wall St. Rank hold SNDX as of Q3 2017.

  • Kornitzer Capital Management reported no remaining Syndax Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Kornitzer Capital Management sold 28,800 Syndax Pharmaceuticals shares in Q3 2017, an estimated $402K.
  • Kornitzer Capital Management first reported a position in Syndax Pharmaceuticals in Q1 2016 and held it in 6 quarters.
  • Kornitzer Capital Management's Syndax Pharmaceuticals position peaked at $559K in Q3 2016.
  • 68 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2017.

Based on Kornitzer Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.